The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease

Journal of the American Society of Nephrology

Volumn 14, Issue 3, 2003, Pages 575-583

  Quarles, L Darryl ^a,g   Sherrard, Donald J ^b   Adler, Stephen ^c   Rosansky, Steven J ^d   McCary, Laura C ^e   Liu, Wei ^e   Turner, Stewart A ^e   Bushinsky, David A ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d WJB Dorn VA Medical Center   (United States)

^e AMGEN INC   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g Duke Ctr for Bone Mineral Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMODIALYSIS; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR SENSITIVITY; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TITRIMETRY; VOMITING;

EID: 0037373070     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000050224.03126.AD     Document Type: Article

References (36)

1. Slatopolsky E, Brown A, Dusso A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37[Suppl 2]: S54-S57, 2001
2. Miyamoto K, Ito M, Segawa H, Kuwahata M: Secondary hyperparathyroidism and phosphate sensing in parathyroid glands. J Med Invest 47: 118-122, 2000
3. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Intl 36: 897-903, 1989
4. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Intl 57: 282-292, 2000
5. Rudnicki M, Hojsted J, Petersen LJ, Sorensen HA, Hyldstrup L, Transbol I: Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: A randomized double-blind placebo-controlled study. Nephron 65: 369-374, 1993
6. Masuyama R, Nakaya Y, Tanaka S. Tsurukami H, Nakamura T, Watanabe S, Yoshizawa T, Kato S, Suzuki K: Dietary phosphorus restriction reverses the impaired bone mineralization in vitamin D receptor knockout mice. Endocrinology 142: 494-497, 2001
7. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29: 641-649, 1997
8. Cunningham J: What is the optimal regimen for vitamin D? Kidney Intl 56: S59-S64, 1999
9. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Intl. 45: 1710-1721, 1994
10. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Intl 46: 1160-1166, 1994
11. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000
12. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
14. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcification in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
15. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
16. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
17. Indridason OS, Quarles LD: Prevention and management of renal osteodystrophy in dialysis patients, In: Renal Osteodystrophy, edited by Bushinskida DA, Philadelphia, Lippincott-Raven, 1997: pp 445-472
18. Hammerland LG, Garrett JE, Hung BCP, Levinthal C, Nemeth EF: Allosteric activation of the calcium receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53: 1083-1088, 1998
19. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045, 1998
20. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391-4396, 1998
21. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Intl 57: 50-58, 2000
22. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Intl 53: 223-227, 1998
23. Nemeth EF: Calcium receptors as novel drug targets, In: Principles in Bone Biology, 1st edition, edited by Bilezikian JP, Raisz LG Rodan GA, San Diego, Academic Press, 1996, pp1019-1035
24. Coburn JW, Barri Y, Turner SA, et al: Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism [Abstract]. J Am Soc Nephrol 11: 573, 2000
25. Goodman WG, Turner SA, Blaisdell PW, et al: Multiple doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism [Abstract]. J Am Soc Nephrol 11: 576, 2000
26. Lindberg JS, Moe SM, Goodman WG, et al: The calcimimetic AMG 073 reduces parathyroid hormone (PTH), phosphorus, and calcium × phosphorus product (Ca × P) in patients with ESRD and secondary hyperparathyroidism [Abstract]. J Am Soc Nephrol 11: 578, 2000
27. Indridason OS Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Intl 57: 282-292, 2000
28. Salem MM: Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 29: 862-865, 1997
29. Martin KJ, Gonzalez EA: Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Di 38[Suppl 53: S34-S40, 2001
30. Kaye M: Hungry bone syndrome after surgical parathyroidectomy. Am J Kidney Dis 30: 730-731, 1997
31. Fox J, Lowe SH, Conkliu RL, Petty BA, Nemeth EF: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 290: 480-486, 1999
32. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis 38[Suppl 5]: S51-S56, 2001
33. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786-1793, 1995
34. Pinggera WF, Popovtzer MM: Uremic osteodystrophy. The therapeutic consequences of effective control of serum phosphorus. JAMA 222: 1640-1642, 1972
35. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11: 330-334, 2000
36. Shoback DM, Bilezikian J, Binder TA, Graves T, Turner SA, Peacock M: Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism [Abstract]. J Bone Miner Res 15: 210, 2000